MK-0683 [vorinostat] Phase1 Clinical Study - Solid Tumor -
Latest Information Update: 06 May 2022
At a glance
- Drugs Vorinostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 26 May 2009 Actual patient number changed from 20 to 16 as reported by ClinicalTrials.gov.
- 08 Sep 2008 Additional trial identifier MK0683-048 reported by ClinicalTrials.gov.
- 08 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.